Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Abstract Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune s...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-93094-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040135579598848 |
|---|---|
| author | Lorena Incorvaia Sarah Scagliarini Fernando Sabino Marques Monteiro Hideki Takeshita Jose Carlos Tapia María Natalia Gandur Quiroga Elaine Lam Deniz Tural Lazar Popovic Saul Campos-Gomez Paolo Andrea Zucali Augusto Mota Cinzia Ortega Juan Pablo Sade Mimma Rizzo Ondřej Fiala Nuno Vau Patrizia Giannatempo Halima Abahssain Andrea Benedetto Galosi Giuseppe Badalamenti Jindrich Kopecky Aristotelis Bamias Johannes Landmesser Jawaher Ansari Fabio Calabrò Francesco Massari Sebastiano Buti Joaquim Bellmunt Matteo Santoni |
| author_facet | Lorena Incorvaia Sarah Scagliarini Fernando Sabino Marques Monteiro Hideki Takeshita Jose Carlos Tapia María Natalia Gandur Quiroga Elaine Lam Deniz Tural Lazar Popovic Saul Campos-Gomez Paolo Andrea Zucali Augusto Mota Cinzia Ortega Juan Pablo Sade Mimma Rizzo Ondřej Fiala Nuno Vau Patrizia Giannatempo Halima Abahssain Andrea Benedetto Galosi Giuseppe Badalamenti Jindrich Kopecky Aristotelis Bamias Johannes Landmesser Jawaher Ansari Fabio Calabrò Francesco Massari Sebastiano Buti Joaquim Bellmunt Matteo Santoni |
| author_sort | Lorena Incorvaia |
| collection | DOAJ |
| description | Abstract Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune systems and urobiome composition. Existing literature data in a pan-cancer context reveal contradictory results, and real-world evidence in urothelial carcinoma (UC) is lacking. This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic urothelial carcinoma (mUC) patients progressing or recurring after platinum-based therapy and treated with pembrolizumab as a part of routine clinical care. A total of 1039 patients, treated from January 1st, 2016 to December 31st, 2023 in 68 cancer centers were included. Our data showed that women with metastatic urothelial carcinoma treated with pembrolizumab had shorter OS than men, with a 13% advantage in the 5-year OS rate for male patients. A deeper understanding of these results may inform sex-stratification in future prospective clinical trials and help develop strategies to reduce the magnitude of the sex disparities observed in urothelial cancer outcomes. |
| format | Article |
| id | doaj-art-56d24ec802e447bd9c9995e0b420ddf4 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-56d24ec802e447bd9c9995e0b420ddf42025-08-20T02:56:09ZengNature PortfolioScientific Reports2045-23222025-03-011511910.1038/s41598-025-93094-2Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia0Sarah Scagliarini1Fernando Sabino Marques Monteiro2Hideki Takeshita3Jose Carlos Tapia4María Natalia Gandur Quiroga5Elaine Lam6Deniz Tural7Lazar Popovic8Saul Campos-Gomez9Paolo Andrea Zucali10Augusto Mota11Cinzia Ortega12Juan Pablo Sade13Mimma Rizzo14Ondřej Fiala15Nuno Vau16Patrizia Giannatempo17Halima Abahssain18Andrea Benedetto Galosi19Giuseppe Badalamenti20Jindrich Kopecky21Aristotelis Bamias22Johannes Landmesser23Jawaher Ansari24Fabio Calabrò25Francesco Massari26Sebastiano Buti27Joaquim Bellmunt28Matteo Santoni29Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of PalermoUOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di NapoliLatin American Cooperative Oncology Group - LACOGDepartment of Urology, Saitama Medical Center, Saitama Medical UniversityDepartment of Medical Oncology, Institut d’Investigació Biomèdica Sant Pau, Hospital de la Santa Creu i Sant PauHospital Ángel H. Roffo, CABAUniversity of Colorado Anschutz Medical CampusDepartment of Medical Oncology, Bakirköy Dr. SadiKonuk Training and Research HospitalOncology Institute of Vojvodina, Faculty of Medicine, University Novi SadCentro Oncologico Estatal ISSEMYMDepartment of Oncology, IRCCS Humanitas Research HospitalClínica AMOMichele and Pietro Ferrero Hospital - ASL CN2Instituto Alexander Fleming, CABADivision of Medical Oncology, A.O.U. Consorziale Policlinico di BariDepartment of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles UniversityUrologic Oncology, Champalimaud Clinical CenterDipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei TumoriMedical Oncology Unit, Medicine and Pharmacy Faculty, National Institute of Oncology, Mohamed V UniversityUrology Unit, Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle MarcheDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of PalermoDepartment of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of AthensKlinik Für UrologieMedical Oncology, Tawam HospitalMedical Oncology 1, IRCCS Regina Elena National Cancer InstituteMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di BolognaMedical Oncology Unit, University Hospital of ParmaDana Farber Cancer Institute, Harvard Medical SchoolOncology Unit, Macerata HospitalAbstract Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and intrinsic differences in local and systemic immune systems and urobiome composition. Existing literature data in a pan-cancer context reveal contradictory results, and real-world evidence in urothelial carcinoma (UC) is lacking. This was a real-world, multicenter, international, observational study to determine the sex effects on the clinical outcomes in metastatic urothelial carcinoma (mUC) patients progressing or recurring after platinum-based therapy and treated with pembrolizumab as a part of routine clinical care. A total of 1039 patients, treated from January 1st, 2016 to December 31st, 2023 in 68 cancer centers were included. Our data showed that women with metastatic urothelial carcinoma treated with pembrolizumab had shorter OS than men, with a 13% advantage in the 5-year OS rate for male patients. A deeper understanding of these results may inform sex-stratification in future prospective clinical trials and help develop strategies to reduce the magnitude of the sex disparities observed in urothelial cancer outcomes.https://doi.org/10.1038/s41598-025-93094-2ImmunotherapyNCT05290038PembrolizumabSex differencesUrothelial Cancer |
| spellingShingle | Lorena Incorvaia Sarah Scagliarini Fernando Sabino Marques Monteiro Hideki Takeshita Jose Carlos Tapia María Natalia Gandur Quiroga Elaine Lam Deniz Tural Lazar Popovic Saul Campos-Gomez Paolo Andrea Zucali Augusto Mota Cinzia Ortega Juan Pablo Sade Mimma Rizzo Ondřej Fiala Nuno Vau Patrizia Giannatempo Halima Abahssain Andrea Benedetto Galosi Giuseppe Badalamenti Jindrich Kopecky Aristotelis Bamias Johannes Landmesser Jawaher Ansari Fabio Calabrò Francesco Massari Sebastiano Buti Joaquim Bellmunt Matteo Santoni Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab Scientific Reports Immunotherapy NCT05290038 Pembrolizumab Sex differences Urothelial Cancer |
| title | Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| title_full | Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| title_fullStr | Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| title_full_unstemmed | Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| title_short | Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| title_sort | sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab |
| topic | Immunotherapy NCT05290038 Pembrolizumab Sex differences Urothelial Cancer |
| url | https://doi.org/10.1038/s41598-025-93094-2 |
| work_keys_str_mv | AT lorenaincorvaia sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT sarahscagliarini sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT fernandosabinomarquesmonteiro sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT hidekitakeshita sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT josecarlostapia sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT marianataliagandurquiroga sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT elainelam sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT deniztural sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT lazarpopovic sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT saulcamposgomez sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT paoloandreazucali sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT augustomota sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT cinziaortega sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT juanpablosade sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT mimmarizzo sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT ondrejfiala sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT nunovau sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT patriziagiannatempo sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT halimaabahssain sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT andreabenedettogalosi sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT giuseppebadalamenti sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT jindrichkopecky sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT aristotelisbamias sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT johanneslandmesser sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT jawaheransari sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT fabiocalabro sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT francescomassari sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT sebastianobuti sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT joaquimbellmunt sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab AT matteosantoni sexasmodifierofsurvivalinpatientswithadvancedurothelialcancertreatedwithpembrolizumab |